Zagami P, Carey LA (2022) Triple negative breast cancer: pitfalls and progress. NPJ Breast Cancer 8:95

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grinda T, Antoine A, Jacot W, Blaye C, Cottu P-H, Diéras V, Dalenc F, Gonçalves A, Debled M, Patsouris A, Mouret-Reynier M-A, Mailliez A, Clatot F, Levy C, Ferrero J-M, Desmoulins I, Uwer L, Petit T, Jouannaud C, Lacroix-Triki M, Deluche E, Robain M, Courtinard C, Bachelot T, Brain E, Pérol D, Delaloge S (2021) Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008–2017 ESME cohort. ESMO Open 6:100114

Article  CAS  PubMed  PubMed Central  Google Scholar 

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2019) Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet 393:1440–1452

Article  Google Scholar 

Bonilla L, Ben-Aharon I, Vidal L, Gafter-Gvili A, Leibovici L, Stemmer SM (2010) Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst 102:1845–1854

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, Kümmel S, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Im S-A, Untch M, Fasching PA, Mouret-Reynier M-A, Foukakis T, Ferreira M, Cardoso F, Zhou X, Karantza V, Tryfonidis K, Aktan G, O’Shaughnessy J (2024) KEYNOTE-522 investigators. overall survival with pembrolizumab in early-stage triple-negative breast cancer. N Engl J Med 391:1981–1991

Article  CAS  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71

Article  PubMed  PubMed Central  Google Scholar 

Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan A-W, Churchill R, Deeks JJ, Hróbjartsson A, Kirkham J, Jüni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Schünemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919

Article  PubMed  PubMed Central  Google Scholar 

Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J (2003) Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 73:712–716

Article  PubMed  Google Scholar 

Bonadio RC, de Sousa IM, Balint FC, Comini ACM, Tavares MC, Madasi F, Bines J, Ferreira RDP, Rosa DD, Santos CL, de Souza ZS (2024) Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer. NPJ Breast Cancer 10(1):73

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bonadio R, Balint F, Souza I, Comini A, et al. Residual Cancer Burden (RCB) with Dose-Dense versus Every 3-Week AC regimen during Neoadjuvant Chemoimmunotherapy for Early-Stage Triple-Negative Breast Cancer – The Neo-Real Study. 2024.

White O, Dent S, Westbrook K, Lee H-J, Yang C, Moore HN (2024) Assessment of efficacy and safety of dose-dense doxorubicin and cyclophosphamide (ddAC) in combination with immunotherapy in early-stage triple-negative breast cancer. Breast Cancer Res Treat 207:179–185

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roman D, Eross M, Mirabile M, Nadour R, et al. Outcomes in early-stage triple negative breast cancer with dose-dense AC as part of a pembrolizumab-based regimen. 2024.

Mai N, Myers S, Shen S, Downs-Canner S, Robson M, Norton L, Chen Y, Traina T, Abuhadra N (2024) Dose dense doxorubicin plus cyclophosphamide in a modified KEYNOTE522 regimen for triple negative breast cancer. NPJ Breast Cancer 10:39

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O’Shaughnessy J (2020) KEYNOTE-522 investigators. Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382:810–821

Article  CAS  PubMed  Google Scholar 

Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer J-U, Grischke E-M, Furlanetto J, Tesch H, Hanusch C, Engels K, Rezai M, Jackisch C, Schmitt WD, von Minckwitz G, Thomalla J, Kümmel S, Rautenberg B, Fasching PA, Weber K, Rhiem K, Denkert C, Schneeweiss A (2019) A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol 30:1279–1288

Article  CAS  PubMed  Google Scholar 

Chen L, Li H, Zhang H, Yang H, Qian J, Li Z, Ren Y, Wang S, Fu P, Yang H, Liu Y (2025) Camrelizumab vs placebo in combination with chemotherapy as neoadjuvant treatment in patients with early or locally advanced triple-negative breast cancer: the camrelief randomized clinical trial. JAMA 333(8):673–681

Article  CAS  PubMed  Google Scholar 

Schmid P, Cortés J, Dent R, Pusztai L, McArthur H, Küemmel S, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M (2024) Abstract LBO1-01: neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study. Cancer Res 84:LBO1-01

Article  Google Scholar 

Helal C, Djerroudi L, Ramtohul T, Laas E, Vincent-Salomon A, Jin M, Seban R-D, Bieche I, Bello-Roufai D, Bidard F-C, Cottu P, Loirat D, Carton M, Lerebours F, Kiavue N, Romano E, Bonneau C, Cabel L (2025) Clinico-pathological factors predicting pathological response in early triple-negative breast cancer. NPJ Breast Cancer 11:15

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384:164–172

Article  PubMed  Google Scholar 

Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG (2022) Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol 23(1):149–160

Article  CAS  PubMed  Google Scholar 

Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE (2021) OlympiA clinical trial steering committee and investigators. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med 384:2394–2405

Article  CAS  PubMed  PubMed Central  Google Scholar 

Masuda N, Lee S-J, Ohtani S, Im Y-H, Lee E-S, Yokota I, Kuroi K, Im S-A, Park B-W, Kim S-B, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H, Jeong J, Kim A, Park K-H, Sasano H, Ohashi Y, Toi M (2017) Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 376:2147–2159

Article  CAS  PubMed  Google Scholar 

Sugiyama K, Gordon A, Popat S, Okines A, Larkin J, Chau I (2025) Is pathological response an adequate surrogate marker for survival in neoadjuvant therapy with immune checkpoint inhibitors? ESMO Open 10:104122

Article  CAS  PubMed  PubMed Central  Google Scholar 

Loibl S, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer JU, Furlanetto J, Zahm DM, Hanusch C, Thomalla J, Jackisch C (2022) Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol 33(11):1149–1158

Article  CAS  PubMed  Google Scholar 

Geyer Jr. CE, Tang G, Nekljudova, V., Rastogi P, et al. (2024) GS3–05 NSABP B-59/GBG-96-GeparDouze—a randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo followed by adjuvant atezolizumab or placebo in patients with stage II and III triple-negative breast cancer

Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, Durando A, Turletti A, Nisticò C, Valle E, Garrone O (2015) Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2× 2 factorial, randomised phase 3 trial. Lancet 385(9980):1863–1872

Article  PubMed  Google Scholar 

Brandberg Y, Johansson H, Hellström M, Gnant M, Möbus V, Greil R, Foukakis T, Bergh J, Swedish Breast Cancer Group, The Austrian Breast, Colorectal Cancer Study Group, The German Breast Cancer Group (2020) Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer. Breast Cancer Res Treat 181:87–96

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schrodi S, Braun M, Andrulat A, Harbeck N, Mahner S, Kiechle M, Klein E, Schnelzer A, Schindlbeck C, Bauerfeind I, Schubert-Fritschle G, Nekljudova V, Mayr D, Weichert W, Denkert C, Loibl S, Engel J (2021) Outcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohort. Ann Oncol 32:1410–1424